Acute Myeloid Leukaemia, Myelofibrosis, Megakaryocytes, Platelets.

Ryan is an Early-Career Researcher working at the Translational Cancer Pathology Laboratory (TCPL) at University of Western Australia.

Ryan's current focus is on the detection of high-risk chromsomal abnormalities (5q/7q and TP53) in acute myeloid leukaemia patients. Ryan has completed a PhD on the dysregulation of megakaryopoiesis and how it is implicated in the progression to myelofibrosis in myeloproliferative disorders.

Ryan has also been involved in mentoring honours and PhD students during his time at TCPL, including teaching experimental techinques, assisting in data analysis and improving the understanding of MPN disease biology.

Ryan's PhD project focused on blood cancers known as Myeloproliferative Neoplasms (MPN), which is comprised of an indolent chronic phase and a more aggressive phase, when the bone marrow begins to scar. Ryan utilised cutting-edge genetic technologies in investigating how DNA changes affect the biology and function of megakaryocytes and cause the cancer to behave so aggressively. DNA changes discovered in Ryan's research is being worked into clinical practice to detect patients whose disease is advancing, leading to the identification of markers that can be targeted with new drugs.

Ryan has developed and optimised cell culture techniques and models for megakaryocyte cell lines and primary cells. Ryan also works with patient material, specifically in isolating different components of peripheral blood and to capture megakaryocytes from bone marrow aspirations. These components are assessed using a mixture of next-generation sequencing, immunohistochemistry, imaging and standard flow cytometry and proteomic analyses.

Ryan's current role as Research Associate involves the development of an imaging flow cytometric method, called immuno-flowFISH, which can simultaneously interrogate the identity of individual cells (immunophenotype) and detect chromosomal abnormalities (FISH). This includes the detection of high-risk abnormalities (i.e 5q/7q and TP53) in blood and bone marrow of MPN and AML patients.

PATH3309 - Cancer Pathology (2021- )

IMED2003 - Medical Scienses Research Methodologies (2021- 2023)

IMED3111 - Intergrated Medical Systems I (2022- )

IMED2001 - Body Defenses (2022)

PATH3305 - Medical Genetics (2023- )

IMED2004 - Huaman Development and Genetics (2024- )

Research Associate at the Translational Cancer Pathology Laboratory (; 2025-now )

Research Assistant at the Translational Cancer Pathology Laboratory (Casual; 2024-2025)

Sponsored research agreement with pharmaceutical industry.